Exelixis, Inc. last reported quarterly results on Oct 29, 2026, for Q3 FY2026 (the quarter ended Oct 2, 2026): revenue of $658.7 million (+10.2% year over year) and diluted EPS of $0.85. It usually reports 10–33 days after a quarter ends. Based on that pattern, the next release is estimated for around Jan 11, 2027.
Results for Q4 FY2026, the quarter ending around Jan 1, 2027. Expected on a Monday. Based on last year's release for the same quarter on Jan 12, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 10–33 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Oct 29, 2026
27 days after quarter end
|
Q3 FY2026
ended Oct 2, 2026
|
659
+10.2%
|
218
+12.7%
|
0.85
+23.2%
|
|
Aug 5, 2026
33 days after quarter end
|
Q2 FY2026
ended Jul 3, 2026
|
629
+10.6%
|
212
+14.7%
|
0.82
+26.2%
|
|
May 5, 2026
32 days after quarter end
|
Q1 FY2026
ended Apr 3, 2026
|
611
+10.0%
|
210
+31.9%
|
0.79
+43.6%
|
|
Jan 12, 2026
10 days after quarter end
|
Q4 FY2025
ended Jan 2, 2026
|
599
+5.6%
|
245
+74.8%
|
0.88
+85.8%
|
|
Nov 4, 2025
32 days after quarter end
|
Q3 FY2025
ended Oct 3, 2025
|
598
+10.8%
|
194
+64.1%
|
0.69
+72.5%
|
|
Jul 28, 2025
24 days after quarter end
|
Q2 FY2025
ended Jul 4, 2025
|
568
-10.8%
|
185
-18.3%
|
0.65
-15.6%
|
|
May 13, 2025
39 days after quarter end
|
Q1 FY2025
ended Apr 4, 2025
|
555
+30.6%
|
160
+327.7%
|
0.55
+358.3%
|
|
Jan 13, 2025
10 days after quarter end
|
Q4 FY2024
ended Jan 3, 2025
|
567
+18.2%
|
140
+63.5%
|
0.48
+74.3%
|
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- EXEL (Nasdaq)
- Fiscal year ends
- January 1
- Incorporated in
- DE
- Headquarters
- Alameda, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 939767
- Former names
- EXELIXIS INC (until Sep 12, 2012)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Neurocrine Biosciences Inc NBIX
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.